Viridian insider corrects holdings by 610 shares

Viridian Therapeutics, Inc. officer Jennifer Tousignant filed an amended Form 4 to correct her reported holdings.

Accepted by SEC EDGAR 03/04/2026 - 07:10 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Viridian Therapeutics, Inc. officer Jennifer Tousignant filed an amended Form 4 to correct her reported holdings. The prior filing inadvertently left out 610 shares that were purchased under the Viridian Therapeutics, Inc. 2016 Employee Stock Purchase Plan. After this correction, she is shown as directly owning 610 common shares.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Tousignant Jennifer

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Holding	Common Stock	--	--	--

Holdings: Common Stock — 610 shares (Direct)

Footnotes (1)

1. F1. This amendment is being filed to correct the number of shares beneficially owned by the Reporting Person as reported in the original Form 4 filed with the Securities and Exchange Commission on March 4, 2025, which inadvertently omitted an aggregate of 610 shares purchased under the Viridian Therapeutics, Inc. 2016 Employee Stock Purchase Plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Viridian Therapeutics (VRDN) Form 4/A amendment report?

The Form 4/A reports a correction to Jennifer Tousignant’s beneficial ownership. It adds 610 Viridian Therapeutics common shares that were previously omitted, all purchased under the company’s 2016 Employee Stock Purchase Plan, and updates her directly owned total to 610 shares.

Who is the insider involved in the Viridian Therapeutics VRDN Form 4/A?

The insider is Jennifer Tousignant, the Chief Legal Officer of Viridian Therapeutics, Inc. The amendment corrects the number of common shares she beneficially owns by including 610 shares purchased under the 2016 Employee Stock Purchase Plan that were omitted in the original Form 4.

How many Viridian Therapeutics VRDN shares does Jennifer Tousignant now report owning?

After the amendment, Jennifer Tousignant reports owning 610 shares of Viridian Therapeutics common stock directly. These 610 shares were previously omitted from her original Form 4 and were purchased through the Viridian Therapeutics, Inc. 2016 Employee Stock Purchase Plan, according to the footnote.

Why was the original Viridian Therapeutics VRDN Form 4 filing corrected?

The original Form 4 was corrected because it inadvertently omitted an aggregate of 610 shares. Those shares had been purchased under the Viridian Therapeutics, Inc. 2016 Employee Stock Purchase Plan, and the Form 4/A amendment updates Jennifer Tousignant’s reported beneficial ownership to include them accurately.

Does the Viridian Therapeutics VRDN Form 4/A show a new stock transaction?

The Form 4/A does not report a new trade; it corrects prior disclosure. It explains that 610 shares purchased under the 2016 Employee Stock Purchase Plan were previously omitted, and now updates Jennifer Tousignant’s reported beneficial ownership to reflect these already acquired shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tousignant Jennifer

(Last) (First) (Middle)

C/O VIRIDIAN THERAPEUTICS, INC.

221 CRESCENT STREET, SUITE 103A

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Viridian Therapeutics, Inc.\DE [ VRDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
03/04/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)								610	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This amendment is being filed to correct the number of shares beneficially owned by the Reporting Person as reported in the original Form 4 filed with the Securities and Exchange Commission on March 4, 2025, which inadvertently omitted an aggregate of 610 shares purchased under the Viridian Therapeutics, Inc. 2016 Employee Stock Purchase Plan.

	/s/Jennifer Tousignant	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.